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a b s t r a c t
In burn patients, wound healing is often accompanied by hypertrophic scarring (HTS),
resulting in both functional and aesthetic problems. HTSs are characterized by abundant
presence of myofibroblasts (MFs) residing in the dermis. HTS development and MF
persistence is primarily regulated by TGF-b signalling. A promising method to target the
transforming growth factor receptor I (TGFbRI; also known as activin-like kinase 5 (ALK5)) is
by making use of exon skipping through antisense oligonucleotides. In HTS the distinguish-
ing border between the papillary dermis and the reticular dermis is completely abrogated,
thus exhibiting a one layered dermis containing a heterogenous fibroblast population,
consisting of papillary fibroblasts (PFs), reticular fibroblasts (RFs) and MFs. It has been
proposed that PFs, as opposed to RFs, exhibit anti-fibrotic properties. Currently, it is still
unclear which fibroblast subtype is most affected by exon skipping treatment.
Therefore, the aim of this study was to investigate the effect of TGFbRI inhibition by exon
skipping in PF, RF and HTS fibroblast monocultures.
Morphological analyses revealed the presence of a PF-like population after exon skipping in
the different fibroblast cultures. This observation was further confirmed by the expression of
genes specific for PFs, demonstrated by qPCR analyses. Further investigations on mRNA and
protein level revealed that indeed MFs and to a lesser extent RFs are targeted by exon
skipping. Furthermore, collagen gel contraction analysis showed that ALK5 exon skipping
reduced TGF-b- induced contraction together with decreased alpha-smooth muscle actin
expression levels.
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In conclusion, we show for the first time that exon skipping primarily targets pro-
fibrotic fibroblasts. This could be a promising step towards reduced HTS development
of burn tissue.
© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The dermis of the skin is divided into two distinct layers; the
superficial, papillary dermis and the deeper, reticular dermis
with both layers differing in morphology and composition.
The papillary dermis is mainly composed of loose matrix
with high cell density. The fibroblasts present in this layer
(PFs) exhibit a spindle- shape appearance when put in
culture. The reticular dermis is composed of a dense matrix,
consisting of mainly reticular fibroblasts (RFs) and low
numbers of myofibroblasts (MFs). The latter types of
fibroblasts have a flat square- shaped appearance when
put in culture and express the biomarker alpha-smooth
muscle actin (aSMA), of which MFs exhibit higher aSMA
expression [1,2].
When trauma causes deep wounds, fibroblasts migrate
towards the wound bed where they differentiate into MFs
under the influence of transforming growth factor-b (TGF-b),
an important regulator in skin homeostasis [3,4]. The main
function of the MFs is to ensure wound healing by extracellular
matrix (ECM) synthesis and contraction of the wound due to
aSMA expression. Upon normal wound closure conditions,
MFs enter apoptosis [3,5]. However, under pathological
conditions, such as HTSs, the MFs remain active and produce
excessive ECM components, in particular collagen type 1 and 3,
leading to fibrotic tissue [6].
Furthermore, when comparing healthy skin to HTS tissue
one can appreciate that the border between the papillary and
reticular dermis, seen in healthy skin, is absent in HTS tissue
due to replacement of both layers by scar tissue [7].
Extrapolating this knowledge to in vitro models, one
encounters a heterogenic fibroblast population upon isolation
of fibroblast from the dermis of HTS tissue, consisting of: PFs,
RFs and MFs. Thus, when investigating the effects of anti-
fibrotic therapies in scar fibroblast (SF) cultures, it is self-
evident that one aims to target the MFs. However, questions
remain about the differential susceptibility of PFs and RFs to
the anti-fibrotic treatment due to the fact that these fibroblast
subtypes also play a role in wound healing [8]. In addition,
several studies have proposed that superficial fibroblasts, i.e.,
PFs, exhibit anti-fibrotic features [912]. Therefore, it would be
of great interest to infer whether one is able to elevate PFs
abundance and, thereby, inducing an anti-fibrotic effect in the
SF culture.
Since the TGF-b signalling pathway plays a prominent role
in HTS development and MFs activity [13,14]. In this this study,
we interfere with the TGF-b pathway by inhibiting TGF-b type I
receptor (TGFbRI), also known as activin-like kinase 5 (ALK5).
Inhibition is established by specifically targeting exon 2, which
encodes the ligand-binding domain of ALK5, using antisense
oligonucleotides. This methodology results in a protein
lacking the ligand-binding domain peptide sequence [15,16].
By targeting the TGF-b signalling pathway we aim to attenuate
the activity of pro-fibrotic RFs and MFs, thereby proving anti-
fibrotic PFs the upper hand.
By assessing the effects of TGF-bRI inhibition on the
different fibroblast subpopulations in SFs cultures, one is able
to provide more information on the functional differences
between the subpopulation which could be a step forward in
the development of a universal HTS treatment option that
could allow reduced HTS development of burn tissue.
Materials and methods
Cell culture
Primary papillary fibroblasts (PFs) (N = 3) and reticular
fibroblasts (RFs) (N = 3) were established from healthy
abdominal or mammary tissue, obtained from cosmetic
surgery. Based on the declaration of Helsinki principles patient
consent was not required since the excised scar tissue was
considered as waste material. Experiments were conducted in
accordance with article 7:467 of the Dutch Law on Medical
Treatment Agreement and the Code for proper Use of Human
Tissue of the Dutch Federation of Biomedical Scientific
Societies (https://www.federa.org/codes-conduct). As of this
national legislation, coded surplus tissue and HTS tissue can
be used for scientific research purposes when no written
objection is made by the informed donor. Therefore, additional
approval of an ethics committee regarding scientific use of
excised HS tissue was not required. Thus, no specific approval
by institutional ethics committee was requested.
Isolation of the PFs and RFs was performed as described
earlier [17]. In short, the papillary and reticular layer were
separated using a dermatome at two different depths. A layer
of 300 mm thickness, containing the epidermis and papillary
layer of which the epidermis was discarded. The second layer
was dermatomed at a depth of 700 mm containing the reticular
layer. Next, the dermal layers were incubated in Collagenase
(Invitrogen, Breda, the Netherlands) and dispase (Roche
Diagnostics, Almere, the Netherlands), mixed in a 3:1 ratio
for 2 h at 37 C. Next, PFs and RFs were isolated.
HTS tissue from three donors was used to isolate the
heterogenic fibroblast population consisting of PFs, RFs and
myofibroblasts (MFs) and will be referred as scar fibroblasts
(SFs). As for the SFs, HTS tissue was cut in pieces of 0.5 cm  0.5
cm and incubated overnight in dispase II at 4 C and
subsequently incubated for 30 min at 37 C for separation of
the epidermis from the dermis. Next, the dermal compartment
was incubated with Collagenase (Invitrogen, Breda, the
Netherlands) and dispase (Roche Diagnostics, Almere, the
Netherlands), mixed in a 3:1 ratio for 2 h at 37 C and the SFs
were isolated. The PFs, RFs and SFs were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) (Gibco/ Invitrogen, Breda,
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the Netherlands) supplemented with 5% fetal bovine serum
(FBS; HyClone, Thermo Scientific, Etten-Leur, the Netherlands)
and 1% penicillinstreptomycin (Thermo Fisher Scientific,
Massachusetts, United States). The fibroblasts were kept at
37 C and 5% CO2 and used for following experiments between
the 3rd and 5th passage.
Next, fibroblasts were plated on 6 cm dished in a density of
5  104 cells per dish and cultured for 24 h. The fibroblasts were
then deprived from serum overnight to be sequentially treated
with recombinant human TGF-b1 (5 ng/ml; Cell Signalling
Technology) and incubated for 24 h. Next, the fibroblasts were
treated with antisense oligonucleotides, consisting of a
scrambled sequence (ScrViM; 2 mM) or exon 2 specific
sequence (ALK5ViM; 2 mM), or pharmacological ALK5 inhibitor
SB431542 (10 mM). The sequences (50-30) of the ViM’s are the
following: ALK5ViM: GCAGTGGTCCTGATTGCAGCAATAT,
ScrViM: CCTCTTACCTCAGTTAC AATTTATA. After 24 h of
incubation culture medium was refreshed and incubated for
an additional three days. Samples were harvested for
sequential analysis.
RNA and protein isolation
The fibroblast monolayer cultures were lysed for RNA and
protein extraction performed with the Favorgen1 (Biotech
corp., Ping-Tung, Taiwan) extraction kit and Tissue Protein
Extraction Reagent (T-PER, Thermo Scientific, Massachusetts,
United States), respectively. Isolations were performed ac-
cording to manufacturer’s protocol.
Quantitative RT-PCR
Total RNA was used for cDNA synthesis, using the iScriptTM
cDNA Synthesis Kit (Bio-Rad Laboratories Inc., Hercules,
California, United States). For qPCR analysis, the cDNA was
amplified in a CFX Real Time Detection system (Bio-Rad
Laboratories Inc., Hercules, California, United States) using
SYBR Green Supermix reagent (Bio-Rad Laboratories Inc.,
Hercules, California, United States). Expression levels of the
following genes were determined: CCRL1, (C-C chemokine
receptor type 11), NTN1 (Netrin-1), PDPN (Podoplanin), TNC
(Tenascin-C), CNN1 (Calponin 1), CDH2 (Cadherin-2), Trans-
glutaminase 2 (TGM2) and ACTA2 (actin-alpha 2). The
expression levels were normalized to reference genes EI24
(Etoposide Induced 2.4), SDHA (Succinate Dehydrogenase
Complex Flavoprotein Subunit A), GOLGA1 (golgin A1), SND1
(Staphylococcal Nuclease And Tudor Domain Containing 1)
and the relative normalized expression levels were calculated
using Bio-rad CFX ManagerTM Version 3.1 (Bio-Rad Laborato-
ries Inc., Hercules, California, United States).
Western Blot
Loading buffer was added 10 mg of each sample and heated to
100 C for five minutes. After a brief centrifugation, the
samples were loaded on MINI-PROTEAN precast gels (Bio-Rad
Laboratories B.V., Veenendaal, Netherlands) for electrophore-
sis. Next, protein was transferred onto a Polyvinylidene
difluoride (PVDF) membrane (Bio-Rad Laboratories B.V.,
Veenendaal, Netherlands) for seven minutes at room
temperature using the Trans-Blot1 TurboTM Transfer System
(Bio-Rad Laboratories B.V., Veenendaal, Netherlands). Subse-
quently, membranes were incubated with the following
primary antibodies overnight at four degrees: Tenascin-C
(TNC) (1:750; Novus Biologicals, Centennial, Colorado, United
States), Transglutaminase 2 (TGM2) (1:750; Abcam, Cambridge,
United Kingdom) and alpha- smooth muscle actin (aSMA)
(1:500; Progen, Heidelberg, Germany). For western blot analysis
to assess basal biomarker levels prior to treatment, the
following antibodies were used: PDPN (1:500; Santa Cruz
Biotechnology, Texas, United States), CDH2 (1:1000; Thermo
Scientific, Massachusetts, United States) and aSMA (1:500;
Progen, Heidelberg, Germany).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
(1:1500, Cell Signaling, Massachusetts, United States) was
used as a loading control. The membranes were then
incubated with a secondary antibody (Pierce, anti-mouse IgG
and anti-rabbit IgG HRP-conjugated, 1:2500 diluted in blocking
buffer) for 60 min. at RT and prepared for visualization using
enhanced chemiluminescence (ECL) substrate solution
(Pierce, SuperSignal West Femto Maximum Sensitivity Sub-
strate) in a dark environment. Visualization was performed
with the ChemiDocTM MP System (Bio-Rad Laboratories B.V.,
Veenendaal, Netherlands).
Contraction of fibroblast populated collagen lattices
Rat collagen was extracted from tail tendons of which the
procedure is described previously [18]. Fibroblast populated
collagen lattices (FPCL) were established by embedding PFs
(N = 3), RFs (N = 3) and SFs (N = 3) into a rat collagen matrix
(4 mg/ ml) at a seeding density of 4  104 cells/ ml. The FPCLs
were cultured for 24 h at 37 C and 5% CO2.
Next, the FPCLs were serum deprived O/N (DMEM,
containing 0.5% FBS; 1% P/S). Serum deprivation was followed
by TGF-b1 (5 ng/ ml) treatment for 6 h and lattices were
sequentially treated with ScrViM (4 mM), ALK5ViM (4 mM) or
SB431542 (10 mM) for 24 h. After 24 h of treatment, the
collagen lattices were refreshed with normal culture medium
(DMEM, containing 5% FBS; 1% P/S) and cultured for an
additional 72 h and harvested. Macroscopic imaging was
performed using a 12-megapixel camera mounted on a
Samsung Galaxy S7 mobile phone (Samsung Electronics
Co., Ltd., Daegu, South Korea). Images were analyzed using
ImageJ and average ration was calculated, in order to quantify
the amount of contraction. Ratio was calculated by dividing
the area of the collagen lattice (in pixel) by the area of the well
(in pixel).
aSMA immunofluorescence staining of FPCLs
Formalin-fixed FPCL cross sections of 5 mm were stained for
aSMA by immunofluorescence.
The FPCL sections were de-paraffinized, rehydrated and
incubated with aSMA (alpha-smooth muscle actin; 1:500;
Progen, Heidelberg, Germany) primary antibody O/N at 4⁰C.
Primary staining was then followed by secondary antibody
incubation (CyTM3 AffiniPure Goat Anti-Mouse; 1:250; Jackson
Immunoresearch Laboratories Inc., Camebridgeshire, United
Kingdom) for 1 h at RT. After antibody incubation, the cells
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were washed with PBS and counterstained the nuclei using
4',6-diamidino-2-phenylindole (DAPI; 1:4000; Carlsbad, Cali-
fornia, United States) and mounted for visualization with
mounting medium that preserves fluorescence (VECTA-
SHIELD, VECTOR Laboratories, Burlingame, California). Quan-
tification of aSMA expression was performed with ImageJ
software. The positive area fraction was calculated by setting
an upper and lower threshold, in order to count the pixels
exhibiting a positive fluorescent signal.
Statistics
The obtained data was transferred to GraphPad Prism version
8.00 for Windows (GraphPad Software, California, United
States). mRNA expression data was analysed using a multiple
t-test  one per row. Statistical analysis on collagen gel
contraction and aSMA immunofluorescence signal were
conducted using a two-way ANOVA test. To adjust for
multiple comparisons, we have used the Holm-Šídák multiple
comparisons test. The differences were noted as follows:
P  0.05, *; P  0.01, **; P  0.001, ***.
Results
Papillary fibroblasts alter in morphology and biomarker gene
expression after exon skipping
In order to investigate if exon skipping could induce a shift in
PF and RF biomarkers, we conducted gene expression analysis
on a panel of biomarkers that were reported by Janson et al. to
be specific for both fibroblast subtypes [1]. For PFs we used
CCRL1, NTN1, PDPN and TNC as biomarkers, while for
validation of RFs we have used CNN1, CDH2 and TGM2 as
biomarkers. To distinguish MFs from RFs and PFs, we used
solely ACTA2 as a biomarker.
Fig. 1 – Brightfield microscopy images and gene expression analysis on PFs. (AH) Images of PFs at basal level (A-D) or stimulated
with TGF-b (E-H). Scale bar: 100 mm. (I and J) Relative normalized fold change expression of PF (CCRL1, NTN1, PDPN and
TNC), RF (CNN1, CDH2 and TGM2) and MF (ACTA2) markers after exon skipping and pharmacological inhibition at basal
level. (K) Effect of TGF-b1 activation displaying normalized relative fold change expression of PF, RF and MF markers. (E
and F) Effect of exon skipping and pharmacological inhibition after TGF-b1 stimulation on relative normalized fold change
expression levels of fibroblast markers. The graph represents the relative normalized mRNA expression values of the
treated samples over their putative control samples (set at one; dashed line). N = 3; error bars represent standard error of
the mean (SEM); *P  0.05; **P  0.01; ***P  0.001; multiple t-test.
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First, we assessed changes in PF morphology after 96 h. In
non- TGF-b-treated PFs (Fig. 1AD) exon skipping (Fig. 1C) did
not affect fibroblast morphology, compared to untreated
(Fig. 1A), ScrViM- treated (Fig. 1B) samples. TGF-b1- stimulat-
ed PFs (Fig. 1EH) showed a polygonal shape (star-like shape)
(Fig. 1E), resembling RFs. Sequential exon skipping (Fig. 2G)
showed that the shape of the fibroblasts obtained a spindle-
shape morphology, hence resembling PFs. A similar observa-
tion was found after SB431542 treatment.
To confirm our observations, we validated fold change
mRNA expression levels of the biomarkers (Fig. 1IM). First,
we investigated the effects of ALK5 exon skipping without
TGF-b stimulation (Fig. 1I). Pharmacological ALK5 inhibitor
SB431542 was used as a positive control (Fig. 1J). Here, we
found that both RFs markers CNN1, CDH2, TGM2, PF marker
NTN1 and MF marker ACTA2 were significantly downregu-
lated (CNN1; P  0.001, CDH2; P  0.01, TGM2; P  0.05, NTN1; P
 0.05 and ACTA2 P  0.05) after exon skipping. SB431542
showed downregulation of CCRL1 (P  0.05), NTN1 (P  0.05),
CDH2 (P  0.05) and ACTA2 (P  0.05) (Fig. 1J). Next, we
assessed the effect of TGF-b1 treatment (Fig. 2K). We found an
elevation of RF markers CDH2 (P  0.001) and TGM2 (P  0.001)
and a significant downregulation of PF biomarkers CCRL1
(P  0.001) and NTN1 (P  0.001). No significant elevation of MF
marker ACTA2 was found. Sequential exon skipping (Fig. 1L)
showed a significant upregulation of PF marker CCRL1
(P  0.05) and downregulation of NTN1 (P  0.05). RF
(CNN1; P  0.001, CDH2; P  0.001 and TGM2; P  0.01) and
MF (ACTA2; P  0.001) markers were all significantly down-
regulated after exon skipping. SB431542 showed a significant
upregulation of PF marker NTN1 (P  0.01) and RF marker
TGM2 (P  0.001). Both RF and MF markers CNN1 (P  0.05) and
ACTA2 (P  0.05) were upregulated in the SB431542 treated
group (Fig. 1M).
Fig. 2 – Brightfield microscopy images and gene expression analysis on RFs. (AD) Morphology of non-TGF-b- treated RFs. (EH)
Images of TGF-b stimulated RFs. Scale bar: 100 mm. (I and J) Relative normalized fold change expression of PF (CCRL1, NTN1,
PDPN and TNC), RF (CNN1, CDH2 and TGM2) and MF (ACTA2) markers after exon skipping and pharmacological inhibition at
basal level. (K) Effect of TGF-b1 activation displaying normalized relative fold change expression of PF, RF and MF markers. (E
and F) Effect of exon skipping and pharmacological inhibition after TGF-b1 stimulation on relative normalized fold change
expression levels of fibroblast markers. The graph represents the relative normalized mRNA expression values of the treated
samples over their putative control samples (set at one; dashed line). N = 3; error bars represent standard error of the mean
(SEM); *P  0.05; **P  0.01; ***P  0.001; multiple t-test.
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Exon skipping affects reticular fibroblast morphology and gene
expression
Next, we assessed the effect of exon skipping on RFs.
Brightfield microscopy images revealed that there were no
changes in morphology at basal level (Fig. 2AD). However,
in the TGF-b-stimulated samples (Figs. 2EH) we observed
that after exon skipping (Fig. 2G) the fibroblasts showed a
more spindle-shape like appearance, compared to TGF-b
stimulation (Fig. 2E) and sequential ScrViM treatment
(Fig. 2F). Sequential SB431542 treatment after TGF-b stimu-
lation showed little presence of spindle-shaped fibroblasts
(Fig. 2H).
mRNA expression analysis of the different fibroblast
markers of the samples at basal level (Fig. 2I) showed that
after exon skipping (Fig. 2C) RF markers (CNN1; P  0.001,
CDH2; P  0.001 and TGM2; P  0.001) and the MF marker ACTA2
(P  0.001) were significantly downregulated. In addition, we
found that three out of four PF markers were significantly
downregulated (NTN1; P  0.001, PDPN; P  0.001 and TNC;
P  0.05), whereas CCRL1 was upregulated (CCRL1; P  0.001).
SB431542 treatment (Fig. 2J) showed a similar effect on RF and
MF markers as was found with exon skipping. As for the PF
marker PDPN, we found a significant downregulation when
treated with SB431542 (P < 0.001) and upregulation of NTN1
(P < 0.001).
Upon TGF-b activation (Fig. 2K) PF markers CCRL1 (P  0.01)
and NTN1 (P  0.001) were substantially downregulated,
whereas PDPN was upregulated (P  0,01). Further, both RF
markers (CNN1; P  0.05 and CDH2; P  0.01) and MF marker
(ACTA2; P  0.05) were significantly upregulated. When TGF-
b-stimulated RFs were sequentially treated with ALK5ViM
(Fig. 2L), we found that all RF and MF markers were
substantially downregulated (CNN1; P  0.001, CDH2;
P  0.001, TGM2; P  0.001 and ACTA2, P  0.001). Expression
levels for PF markers showed a similar effect as found in non
TGF-b- stimulated RFs (Fig. 2I). When TGF-b activation was
followed by SB431542 treatment (Fig. 2M), the effect on PF
markers was similar as determined for SB431542 at basal level.
Further,SB431542 treatmentinducedsignificantdownregulation
of RF marker CDH2 (P  0.01) and MF markers ACTA2 (P  0.01).
Exon skipping induces a shift in fibroblast markers in scar
fibroblasts
Next, fibroblasts derived from HTS tissue were examined. As
shown in Fig. 3A, the dermis of normal human skin displays a
clear border between the papillary (I) and reticular dermis (II).
This makes it relatively easy to isolate fibroblasts from the
respective dermal layers. However, in the dermis of HTS tissue
this border is absent (Fig. 3B; III), which makes it impossible to
macroscopically distinguish between PFs, RFs and MFs.
Therefore, we isolated the complete HTS fibroblast population
referred to SFs.
Morphology of the SFs at basal level showed abundance of
spindle-shaped fibroblasts and to lower extent presence of
polygonal shaped fibroblasts (Fig. 4AD). Treatment with
ALK5ViM or SB431542 did not affect the morphology of the
fibroblasts. Upon TGF-b activation (Fig. 4E), we found that
fibroblast morphology obtained an overall polygonal appear-
ance and sequential treatment with the control oligonucleo-
tide ScrViM did not affect fibroblast morphology (Fig. 4F).
However, when TGF-b- stimulated SFs were treated with
ALK5ViM we observed a shift in morphology towards a
spindle-shape like appearance (Fig. 4G). A similar effect was
found after SB431542 treatment (Fig. 4H).
Gene expression analysis at basal level showed that exon
skipping only showed a downregulation in RF marker CNN1 (P
 0.001) and MF marker ACTA2 (P  0.001) (Fig. 4I). Pharmaco-
logical inhibitor SB431542 showed substantial upregulation of
PF markers CCRL1 (P  0.05), NTN1 (P  0.05) and PDPN (P  0,01)
(Fig. 4J). TCN was downregulated in the SB431542 treated group
(P  0.01). Further, pharmacological ALK5 inhibition showed
downregulation of TGM2 (P  0.01) and ACTA2 (P  0.01).
Next, SFs were activated with TGF-b1 (Fig. 4K) and we found
a significant downregulation of PF markers CCRL1 (P  0.001),
NTN1 (P  0.01) and elevated TNC expression levels (P  0.05).
All RF markers (CNN1; P  0.001, CDH2; P  0.001 and TGM2;
P  0.001) together with MF marker (ACTA2; P  0.001) were
significantly upregulated. Sequential exon skipping (Fig. 4L)
showed a substantial downregulation of RF markers CNN1
(P  0.001), CDH2 (P  0.001) and MF marker ACTA2 (P  0.001).
Further, ALK5ViM induced significant elevation of PF markers
Fig. 3 – Histological characteristics of the dermis of normal skin and HTS tissue. (A) Hematoxylin and Eosin staining of normal
skin. The red line displays the border between the two layers of the dermis: (I) Papillary dermis and (II) Reticular dermis. (B)
Dermis of HTS tissue where the border between the papillary and reticular layer is abrogated due to replacement of scar tissue B
(III). Scale bar: 100 mm (For interpretation of the references to colour in this figure legend, the reader is referred to the web version
of this article).
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CCRL1 (P  0.001) and NTN1 (P  0.05). PDPN and TNC
expression levels were not affected. Further, SB431542 showed
a significant downregulation of all RF markers (P  0.001) and
ACTA2 (P  0.001) expression levels (Fig. 4M). Furthermore,
SB431542 showed a significant upregulation of CCRL1
(P  0.001), NTN1 (P  0.05), PDPN (P  0.01) and TNC (P  0.05).
TGF-b1- activated papillary fibroblasts, reticular fibroblasts
and scar fibroblasts show reduced tenascin-C (TNC) expression
after exon skipping
After confirmation at gene expression level, we continued with
protein expression of fibroblast biomarkers. Therefore, we
selected the PF marker tenascin-C (TNC) and RF marker
transglutaminase 2 (TGM2), since these proteins have been
reported to be highly expressed in PFs and RFs, respectively.
aSMA was used as a biomarker for MFs [19].
Fig. 5 shows western blots of the different fibroblast
markers TNC, TGM2, aSMA and reference protein GAPDH at
basal level and after TGF-b1 activation in the different
fibroblast cultures. Because of high donor variability, no
statistical significant differences were found between con-
ditions. However, for some conditions a clear trend was
observed.
In PFs (Fig. 5A) we observed a reduction in TNC protein
expression after exon skipping. This effect was most pro-
nounced in the TGF-b- stimulated group. Although, sequential
SB431542 treatment showed a reduction in TNC expression to
a lesser extent. TGM2 showed overall weak expression at basal
level. In the TGF-b-stimulated group, we observed a slight
reduction in TGM2 expression after treatment with ScrViM
and ALK5ViM. After SB431542 treatment, two out of three
donors exhibited substantial downregulation of TGM2. MF
marker aSMA was evenly downregulated by ScrViM and
Fig. 4 – Morphology and gene expression analysis on SFs. (A-D) Morphology of SFs at basal level. (E-H) TGF-b activated SFs. Scale
bar: 100 mm. (I and J) Relative normalized fold change expression of PF (CCRL1, NTN1, PDPN and TNC), RF (CNN1, CDH2
and TGM2) and MF (ACTA2) markers after exon skipping and pharmacological inhibition at basal level. (K) Effect of TGF-
b1 activation displaying normalized relative fold change expression of PF, RF and MF markers. (E and F) Effect of exon
skipping and pharmacological inhibition after TGF-b1 stimulation on relative normalized fold change expression
levels of fibroblast markers. The graph represents the relative normalized mRNA expression values of the treated
samples over their putative control samples (set at one; dashed line). N = 3; error bars represent standard error of the
mean (SEM); *P  0.05; **P  0.01; ***P  0.001; multiple t-test.
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ALK5ViM at basal level and to lesser extent by SB431542
treatment. In the TGF-b-activated group exon skipping
induced a substantial reduction of aSMA in two out of three
donors.
In RFs (Fig. 5B) we observed a considerable reduction in TNC
expression after exon skipping in the TGF-b-stimulated group.
TGM2 showed overall weak protein expression on the
immunoblots, however after quantification we observed a
similar effect of ALK5 exon skipping in the TGF-b-activated
group as was found observed for TNC. No large changes were
observed after SB431542 treatment. Further, no changes were
found in aSMA expression after ALK5 inhibition in the non
TGF-b-treated and TGF-b-treated group.
Regarding the SF cultures (Fig. 5C), a similar effect was
observed on TNC expression by ALK5 exon skipping as was
found in PF and RF cultures. Further, as reported earlier for
TGM2 expression, overall weak expression was observed. At
basal level, a similar trend was observed in TGM2 expression as
was observed in RFs. In the TGF-b- stimulated group two out of
three donors were upregulated compared to the control
sample after ALK5 exon skipping. As for aSMA, ALK5 exon
skipping showed a slight increase in protein expression at
basal level. TGF-b activation followed by ScrViM, ALK5ViM or
SB431542 treatment showed a similar reduction in aSMA
expression as was observed in RFs.
Differential effect on collagen contraction by fibroblast
subtypes
Next, we investigated the extent to which the different
fibroblast subtypes affect contraction and if we could inhibit
contraction using exon skipping. Therefore, we established
FPCLs in which we embedded PFs, RFs or SFs and assessed the
extent of contraction (Fig. 6AD). In addition, we assessed
whether changes in contraction correlated with aSMA
expression (Fig. 6EG).
PF-containing collagen lattices (Fig. 6A) showed 25%
contraction at basal level compared to the RF- (Fig. 6B) and
SF- based collagen lattices (Fig. 6C). TGF-b1 stimulation
showed a slight increase in contraction of the PF- containing
collagen gel, however, not significant (Fig. 6A; TGF-b).
Following TGF-b stimulation with sequential ScrViM treat-
ment, did not show any substantial changes in contraction
(Fig. 6A; TGF-b + ScrViM). Sequential exon skipping treatment
(Fig. 6A; TGF-b + ALK5ViM) showed a significant reduction in
contraction compared to the control condition (P  0.001)
(Fig. 6D). Although not significant, SB431542 treatment
substantially reduced contractility compared to control con-
ditions (Fig. 6A; SB431542 and TGF-b + SB431542). aSMA
expression showed no dramatic changes between the differ-
ent conditions (Fig. 6E).
Fig. 5 – Immunoblotting of fibroblast marker expression in the different fibroblast cultures. Representative western blots and
quantification for (A) PFs (N = 3), (B) RFs (N = 3) and (C) SFs (N = 3). For all fibroblast cultures the expression of TNC (PF marker),
TGM2 (RF marker) and aSMA (MF marker) was assessed. GAPDH was used as a loading control. Relative intensity of TNC, TGM2
and aSMA was calculated by dividing the band intensity of the protein of interest by the corresponding GAPDH band intensity.
Normalization was performed by dividing the relative band intensity of the treatment by their respective control samples (Ctrl
or TGF-b, set at one; dashed line). Each symbol shape represents a different donor.
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The collagen lattices embedded with RFs (Fig. 6B) showed
high contraction at basal level, compared to PF collagen
lattices (Fig. 6D). Exon skipping did not show any reduction at
basal level (Fig. 6B; ALK5ViM). In addition, TGF-b1 stimulation
(Fig. 6B; TGF-b) did not show major effects on contractility
of the collagen lattices. Exon skipping showed a slight
reduction in contraction of the RF collagen lattices (Fig. 6B;
TGF-b + ALK5ViM), whereas the pharmacological inhibitor
was not able to counteract the effect of TGF-b1 (Fig. 6B;
TGF-b + SB431542). aSMA immunofluorescence staining
showed that RF containing lattices (Fig. 6F) exhibited higher
expression levels compared to PF embedded lattices (Fig. 6E).
ALK5 inhibition did not affect aSMA expression in RF
containing FPCLs.
SF- containing collagen lattices (Fig. 6C) showed overall
significant contraction, compared to PF collagen gels (P  0.001)
(Fig. 6D). Furthermore, exon skipping and pharmacological
ALK5 inhibition showed a slight reduction in contraction at
basal level (Fig. 6C; ALK5ViM and SB431542; Fig. 6D) compared
to control samples. Furthermore, TGF-b1 stimulation showed
high contractility (Fig. 6C; TGF-b, TGF-b + ScrViM and Fig. 6D).
The effect of TGF-b1 was counteracted with ALK5 exon
skipping, compared to TGF-b1 treated samples (P  0.01)
and TGF-b1 + ScrViM samples (P  0.05) (Fig. 6C and D).
SB431542 showed a slight reduction in contraction compared
to TGF-b1 treated samples, however, this effect was not as
pronounced as with exon skipping. Furthermore, aSMA
expression in the FPCLs followed the changes in contraction
that were calculated in Fig. 6D (Fig. 6EG). Quantification of IF
images (Fig. 6H) revealed that PF-containing FPLCs possessed
lower aSMA compared to whereas RF- and SF-containing
FPLCs.
Fig. 6 – Contraction assay of FPCLs established with PFs, RFs or SFs. (AC) Images of the different FPCLs after 96 h. The type of
treatment is indicated in the upper left corner of each image (D) Analysis of contraction of the different collagen lattices after 96 h.
Quantification was performed using ImageJ. The amount of contraction was calculated by dividing the area of the lattice (in
pixels) by the area of the well (pixels). The bar graphs represent the average ration of the different fibroblast populations: PF
(black), RF (dark grey) and SF (grey). (EH) Immunofluorescence staining for aSMA on the different FPCLs and quantification of
the aSMA positive area. Total magnification of the images: 200  . N = 3 per fibroblast population; error bars represent standard
error of the mean (SEM); *P  0.05; **P  0.01; ***P  0.001; two-way ANOVA.
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Discussion
In this study, we aimed to unravel which dermal fibroblasts
subtype is affected by exon skipping. Numerous studies have
investigated the differential expression profiles between PFs
and RFs, reporting new additional markers to distinguish
between different fibroblast subtypes [1,2024]. As a result of
these new insights, our understanding of fibroblast heteroge-
neity is becoming increasingly complex. However, to
this date information is scarce on the effect of TGF-b
modulation on the different fibroblast subsets in HTSs or
fibrosis in general. Moreover, it is unknown to what extent
this affects the function of the different fibroblast subtypes.
For this reason, we assessed the effects of exon skipping on
morphology, gene and protein expression profiles of the
different fibroblast cultures. In addition, we investigated the
behaviour of the different fibroblast cultures with respect to
contraction upon exon skipping. Especially PFs, residing in
the superficial dermis, were of great interest, since it has been
reported that superficial dermal fibroblasts are anti-fibrotic
[12].
Exon skipping revealed a spindle shape- like appearance in
the TGF-b1 stimulated groups in all fibroblast cultures, hence
resembling PFs. This effect was less pronounced at basal
levels. A possible explanation for this result could be
addressed to the fact that dermal fibroblasts express persis-
tent levels of ALK5 during wound healing and hypertrophic
scars [25]. Furthermore, HTSs exhibit high concentrations of
myofibroblast abundance [25,26]. Together, this could explain
why fibroblasts start to express higher levels of ALK5 in a
fibrotic environment, thus after TGF-b1 activation, and
therefore being more susceptible for exon skipping of the
ALK5 ligand binding domain. Gene expression analysis
confirmed that the effect of ALK5 exon skipping on the
markers of the pro-fibrotic RFs and MFs was most pronounced
in the TGF-b1- stimulated samples. In addition, the fibrotic
effect found after TGF-b1 was in agreement with a previous
study that reported that TGF-b1-treated PFs differentiation
towards RFs. This was confirmed by a significant down-
regulation of papillary markers NTN1 and PDPN together with
an upregulation of reticular and myofibroblast markers CNN1,
CDH2, TGM2 and aSMA [4]. One would expect that after exon
skipping PF markers would show an upregulation of mRNA
expression levels. Unexpectedly, this was only the case for PF
marker CCRL1. NTN1, PDPN and TNC were not affected or even
downregulated. Although the function of these markers in PFs
still has to be elucidated fully, one could hypothesize that
NTN1 and PDPN are downregulated by modulation of the TGF-
b signalling pathway by e.g., ALK5 exon skipping. With regard
to PF marker gene expression and the potentially anti-fibrotic,
spindle shape-like appearance we found that in all cases of the
anti-fibrotic phenotype CCRL1 was highly upregulated. This
result could indicate that CCRL1 correlates with the re-
appearance of PF-like fibroblasts after ALK5 inhibition, and
potentially an anti-fibrotic phenotype. One way to confirm
whether the PF-like cells indeed possess anti-fibrotic charac-
teristics as described in literature, would be to determine
decorin expression before and after re-activation with TGF-b1.
Since decorin hampers TGF-b1 signalling, activation of TGF-b
downstream targets should be reduced in these fibroblast
cultures [44,45].
Next, we assessed protein expression of fibroblast markers
TNC, TGM2 and aSMA. The rationale behind the selection of
different markers was based on previous studies conducted by
Janson and colleagues who used these markers successfully
for western blot analysis to differentiate between PFs, RFs and
MFs [4,27].
In contrast to earlier findings that showed distinct in vitro
TNC expression levels between PFs (high) and RFs (low), it was
striking to find that this marker showed considerable weak
protein expression in our non-TGF-b stimulated PF cultures
[1,2]. Speculatively TNC expression could change in PF
cultures after prolonged culturing, thus reducing in activity
over time. Moreover, when PFs were stimulated with TGF-b1,
TNC expression was substantially elevated. A possible
explanation for this apparently opposite effect could be
derived from previous studies that have found a similar effect
of TGF-b1 on TNC expression in human dermal fibroblasts by
activation of the Tnc promotor through binding SMAD2 and
SMAD3 [28,29]. Remarkably, we observed that PF marker TNC
was downregulated after exon skipping in the TGF-b1-
stimulated groups in all three fibroblast cultures. However,
according to the observed changes in fibroblast morphology
towards a PF-like phenotype, we expected TNC to be
upregulated after exon skipping. Moreover, de novo TNC
expression has been described to be a hallmark of inflamma-
tion, thus during the inflammatory phase of wound healing
[30]. Furthermore, it has been reported that TNC expression is
inhibited after normal scar development and shows persis-
tence during HTS development [31]. Thus, although TNC is
considered a marker of the papillary dermis and PFs, it has
been suggested that TNC could also be a pro-fibrotic
component, which could be downregulated using exon
skipping as reported in our present study. RF marker TGM2
did not show any major changes at basal and TGF-b1
activated conditions. A previous study, conducted by Janson
and colleagues, TGM2 expression was found to be higher in
most RF monocultures compared to PF cultures at protein
level [1]. Therefore, we selected TGM2 as a RF marker to assess
its expression using western blot. However, in contrast with
differential expression found in the study of Janson et al., we
found no differences between PFs and RFs for TGM2. Further,
in contrast with earlier findings and TGM2 gene expression in
this study, no elevated TGM2 expression was found after TGF-
b1 stimulation [4,32]. Based on protein data, it seems that
TGM2 was not a suitable marker in this study, compared to
previous studies. Therefore, it is warranted to use other RF
markers for future experimentation, for example CNN1 [1].
Furthermore, ALK5 exon skipping reduced aSMA expression
in the TGF-b- activated groups in the different fibroblast
cultures. However, the scrambled AON sequence showed a
similar reduction of aSMA. This observation suggests that the
vivo-morpholino itself is primarily responsible for this effect
on aSMA [33]. In order to observe a considerably effect of
ALK5ViM, one could increase ViM concentrations and/or
extend culturing. However, in the case of increasing AON
concentration one should be careful, since ViMs could cause
cytotoxicity at higher concentrations [33,34]. Strikingly,
pharmacological ALK5 inhibition even showed upregulation
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of aSMA in the TGF-b-stimulated groups of the RF and SF
cultures. This effect could be explained by the difference in
inhibition of the TGF-b signalling pathway by ALK5ViM and
SB431542: ALK5ViM is able to inhibit the TGF-b-dependent
SMAD and TGF-b- independent mitogen-activated protein
kinase (MAPK) signalling pathway. Whereas SB431542 only
inhibits the SMAD- dependent signalling pathway [35,36].
Therefore, upon SB431542 treatment in the TGF-b-activated
group the inhibitory effect SMDAD2/3 inhibition is bypassed
by a possible overactivation of MAPK in RF and SF cultures.
This phenomenon could also explain the differential effect on
gene expression between ALKViM and SB431542: CNN1, CDH2
and TGM2 are all associated with TGF-b signalling
[3740]. Since ALK5 exon skipping inhibits both canonical
and non-canonical TGF-b signalling, we found more consis-
tent downregulation of these pro-fibrotic RF markers. As
mentioned earlier, PF markers also showed differential
expression depending on exon skipping or pharmacological
inhibition. Another explanation for this observation
could be that activation of TGF-b signalling in an ALK5-
independent manner [41,42]. Additional western blot analy-
ses of basal expression levels of PDPN (PF), CDH2 (RF) and
aSMA (MF) revealed that PF cultures primarily express PDPN,
whereas RF and SF cultures both possess high expression
levels of CDH2 and aSMA (Supplementary Figure S1), thus
suggesting that PDPN and CHD2 should be taken along in
further experimentation with a broader fibroblast biomarker
panel. Altogether, these hypotheses require further investi-
gation. Furthermore, a more elaborate fibroblast marker
panel should be included in the experiments in order to
elucidate the effect of ALK5 inhibition on the different
fibroblast subtypes.
As confirmed by conducting a collagen gel contraction
assay, we found that exon skipping was able to signifi-
cantly reduce contraction and counteract TGF-b1-induced
contraction, compared to control conditions. In agreement
with the hypothesis that PFs exhibit anti-fibrotic features,
we found that PF-embedded collagen gels showed overall
significant lower contraction compared to collagen gels
embedded with RFs and SFs at basal level and after TGF-b1
activation (P < 0.001) [43]. This finding could suggest that
PFs are able to inhibit activated TGF-b1 residing in the ECM
through the actions of decorin, which has been reported to
be primarily expressed in the papillary dermis and is
known to inhibit actions of TGF-b144,45]. In addition,
reduced decorin expression is linked to HTS development
[46].
Furthermore, contraction of FPCLs embedded with RFs
resembled the contraction of SF-embedded lattices. This
finding supports the resemblance of RFs and MFs, since the SF
cultures also harbour MFs. In the study performed by Janson
and colleagues, it has been proposed that RFs harbour low
aSMA expression and, therefore, showing a more differenti-
ated state compared to PFs. Thus, making RFs more prone to
differentiating into MFs. In addition, several validated RF
markers are associated with MFs [4749]. In agreement with
these findings, we observed higher aSMA expression in RF
and SF containing FPCLs compared to PF-containing FPCLs.
Further, aSMA expression followed contraction observed in
the FPCLs and was reduced by ALK5 exon skipping especially
in the TGF-b- stimulated groups. Moreover, human skin
equivalents embedded with RFs showed higher contraction
compared to those embedded with PFs [1]. Therefore, it would
be of great interest to assess the effect of ALK5 exon skipping
on different fibroblasts populations in a more advanced 3D
model, such as human skin equivalents.
Considering the differentiation of PFs into MFs one can
appreciate that this is a step-wise process in which the PFs
differentiate into an intermediate state: the RF. However,
proof that this process is probably more nuanced is the
presence of so-called proto-MFs [50]. It has been proposed
by Tomasek and colleagues that during wound healing
fibroblasts differentiate to proto-MFs, primarily under
mechanical tension caused by fibroblasts migrating via
professional collagen bundles towards the wound bed.
Next, TGF-b1 causes differentiation to mature MF [50]. The
main difference between a proto-MF and mature MF is the
former lacks aSMA expression and only expresses cyto-
plasmic b and g actins. Therefore, by combining our
findings together with data reported in the previous
studies by Janson et al. and Tomasek et al., we propose
that upon wound healing (and eventual HTS formation by
MF persistence) PFs differentiate, due to tensional forces,
into fibroblasts that express stress fibres that only express
cytoplasmic b and g actins (proto- MF) [1,50]. Next, TGF-b1
secreted by proto-MFs together with activated extracellu-
lar TGF-b1 and ongoing tensional forces ensure differen-
tiation into RFs, expressing low levels of aSMA. Because of
persistent mechanical stress and TGF-b1 secretion, the
RFs differentiate into mature MFs [4,5053]. Furthermore,
a recent study reported the identification of functionally
distinct fibroblast populations in the lower dermis and
reticular dermis, of which two subtypes were reported to
be as yet uncharacterized fibroblast subpopulations and
could provide new insights on the presence and location of
the proto-MFs, since it is known that the reticular dermis
shows low MF abundance and thereby possibly presence of
proto-MFs [23].
Altogether, our findings show that we were able to
reduce presence of pro-fibrotic features in the heteroge-
neous SF population using exon skipping. In addition, we
were able to maintain the desirable features to establish
proper wound healing. In order to determine the stability
of the phenotypes of the different fibroblast cultures,
together with their specific features, it is warranted to
continue with longevity studies. Phenotype studies could
be conducted in 2D culture models. The long-term effects
could be studied in 3D human skin equivalents, such as
fibroblast-derived matrix models which could be estab-
lished with PFs, RFs or SFs [54]. Furthermore, it would be of
great interest to assess whether our approach could be
useful in establishing skin substitutes in order to treat
burn victims and, thereby, reducing severe scarring or
even a step closer to scar-free wound healing.
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